Advertisement

Bioprocess development of a stable FUT8−/−-CHO cell line to produce defucosylated anti-HER2 antibody

  • Yuan Yuan
  • Huifang Zong
  • Jingyi Bai
  • Lei Han
  • Lei Wang
  • Xinyu Zhang
  • Xiaoshuai Zhang
  • Jingyi Zhang
  • Chenxiao Xu
  • Jianwei Zhu
  • Baohong ZhangEmail author
Research Paper
  • 37 Downloads

Abstract

In recent years, an increasing number of defucosylated therapeutic antibodies have been applied in clinical practices due to their better efficacy compared to fucosylated counterparts. The establishment of stable and clonal manufacturing cell lines is the basis of therapeutic antibodies production. Bioprocess development of a new cell line is necessary for its future applications in the biopharmaceutical industry. We engineered a stable cell line expressing defucosylated anti-HER2 antibody based on an established α-1,6-fucosyltransferase (FUT8) gene knockout CHO-S cell line. The optimization of medium and feed was evaluated in a small-scale culture system. Then the optimal medium and feed were scaled up in a bioreactor system. After fed-batch culture over 13 days, we evaluated the cell growth, antibody yield, glycan compositions and bioactivities. The production of anti-HER2 antibody from the FUT8 gene knockout CHO-S cells in the bioreactor increased by 37% compared to the shake flask system. The N-glycan profile of the produced antibody was consistent between the bioreactor and shake flask system. The antibody-dependent cellular cytotoxicity activity of the defucosylated antibody increased 14-fold compared to the wild-type antibody, which was the same as our previous results. The results of our bioprocess development demonstrated that the engineered cell line could be developed to a biopharmaceutical industrial cell line.

Keywords

Bioprocess development CHO cells Defucosylated antibodies Fed-batch Stable cell line 

Notes

Acknowledgements

This project was supported by National Science Foundation of China [Grant number: 81502969].

Compliance with ethical standards

Conflict of interest

All the authors reviewed and agreed to submit this manuscript. The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

The study does not contain experiments using animals and human studies.

References

  1. 1.
    Weiner GJ (2015) Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 15(6):361–370CrossRefGoogle Scholar
  2. 2.
    Aggarwal SR (2014) What's fueling the biotech engine—2012 to 2013. Nat Biotechnol 32(1):32–39CrossRefGoogle Scholar
  3. 3.
    Kunert R, Reinhart D (2016) Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol 100(8):3451–3461CrossRefGoogle Scholar
  4. 4.
    Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30(5):1158–1170CrossRefGoogle Scholar
  5. 5.
    Hiller GW, Ovalle AM, Gagnon MP, Curran ML, Wang W (2017) Cell-controlled hybrid perfusion fed-batch CHO cell process provides significant productivity improvement over conventional fed-batch cultures. Biotechnol Bioeng 114(7):1438–1447CrossRefGoogle Scholar
  6. 6.
    Vogel JH, Anspach B, Kroner KH, Piret JM, Haynes CA (2002) Controlled shear affinity filtration (CSAF): A new technology for integration of cell separation and protein isolation from mammalian cell cultures. Biotechnol Bioeng 78(7):805–813CrossRefGoogle Scholar
  7. 7.
    Reusch D, Tejada ML (2015) Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25(12):1325–1334CrossRefGoogle Scholar
  8. 8.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of Fc gamma RIIIa functional polymorphism. Clin Cancer Res 10(18):6248–6255CrossRefGoogle Scholar
  9. 9.
    Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5):3466–3473CrossRefGoogle Scholar
  10. 10.
    Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol 336(5):1239–1249CrossRefGoogle Scholar
  11. 11.
    Zhang X, Han L, Zong H, Ding K, Yuan Y, Bai J, Zhou Y, Zhang B, Zhu J (2018) Enhanced production of anti-PD1 antibody in CHO cells through transient co-transfection with anti-apoptotic genes Bcl-xL and Mcl-1. Bioprocess Biosyst Eng 41(5):633–640CrossRefGoogle Scholar
  12. 12.
    Wong AW, Baginski TK, Reilly DE (2010) Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng 106(5):751–763CrossRefGoogle Scholar
  13. 13.
    Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5):614–622CrossRefGoogle Scholar
  14. 14.
    Zong HF, Han L, Ding K, Wang JX, Sun T, Zhang XY, Cagliero C, Jiang H, Xie YQ, Xu JR, Zhang BH, Zhu JW (2017) Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via FUT8 knockout CHO-S cells. Eng Life Sci 17(7):801–808CrossRefGoogle Scholar
  15. 15.
    Sun T, Li C, Han L, Jiang H, Xie Y, Zhang B, Qian X, Lu H, Zhu J (2015) Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody. Eng Life Sci 15(6):660–666CrossRefGoogle Scholar
  16. 16.
    Hober S, Nord K, Linhult M (2007) Protein A chromatography for antibody purification. J Chromatogr B 848(1):40–47CrossRefGoogle Scholar
  17. 17.
    Ding K, Han L, Zong H, Chen J, Zhang B, Zhu J (2017) Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein. Appl Microbiol Biot 101(5):1889–1898CrossRefGoogle Scholar
  18. 18.
    Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG (2000) Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164(8):4178–4184CrossRefGoogle Scholar
  19. 19.
    Junttila TT, Parsons K, Olsson C, Lu YM, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70(11):4481–4489CrossRefGoogle Scholar
  20. 20.
    Collins D, O'donovan N, McGowan P, O'sullivan F, Duffy M, Crown J (2011) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23(7):1788–1795CrossRefGoogle Scholar
  21. 21.
    Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033CrossRefGoogle Scholar
  22. 22.
    Templeton N, Smith KD, McAtee-Pereira AG, Dorai H, Betenbaugh MJ, Lang SE, Young JD (2017) Application of 13C flux analysis to identify high-productivity CHO metabolic phenotypes. Metab Eng 43:218–225CrossRefGoogle Scholar
  23. 23.
    Ahn WS, Antoniewicz MR (2011) Metabolic flux analysis of CHO cells at growth and non-growth phases using isotopic tracers and mass spectrometry. Metab Eng 13(5):598–609CrossRefGoogle Scholar
  24. 24.
    Ma NN, Ellet J, Okediadi C, Hermes P, McCormick E, Casnocha S (2009) A single nutrient feed supports both chemically defined NS0 and CHO fed-batch processes: improved productivity and lactate metabolism. Biotechnol Progr 25(5):1353–1363CrossRefGoogle Scholar
  25. 25.
    Luo J, Vijayasankaran N, Autsen J, Santuray R, Hudson T, Amanullah A, Li F (2012) Comparative metabolite analysis to understand lactate metabolism shift in Chinese hamster ovary cell culture process. Biotechnol Bioeng 109(1):146–156CrossRefGoogle Scholar
  26. 26.
    Curthoys NP, Watford M (1995) Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15:133–159CrossRefGoogle Scholar
  27. 27.
    Cai W-F, Zhang C, Wu Y-Q, Zhuang G, Ye Z, Zhang C-S, Lin S-C (2018) Glutaminase GLS1 senses glutamine availability in a non-enzymatic manner triggering mitochondrial fusion. Cell Res 28(8):865–867CrossRefGoogle Scholar
  28. 28.
    Chen P, Harcum SW (2005) Effects of amino acid additions on ammonium stressed CHO cells. J Biotechnol 117(3):277–286CrossRefGoogle Scholar
  29. 29.
    Hong MS, Severson KA, Jiang M, Lu AE, Love JC, Braatz RD (2018) Challenges and opportunities in biopharmaceutical manufacturing control. Comput Chem Eng 110:106–114CrossRefGoogle Scholar
  30. 30.
    Martin I, Wendt D, Heberer M (2004) The role of bioreactors in tissue engineering. Trends Biotechnol 22(2):80–86CrossRefGoogle Scholar
  31. 31.
    Obom KM, Magno A, Cummings PJ (2013) Operation of a benchtop bioreactor. JoVE J Vis Exp 79:e50582Google Scholar
  32. 32.
    O’Mara P, Farrell A, Bones J, Twomey K (2018) Staying alive! Sensors used for monitoring cell health in bioreactors. Talanta 176:130–139CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of PharmacyShanghai Jiao Tong UniversityShanghaiPeople’s Republic of China
  2. 2.Jecho Laboratories, Inc.FrederickUSA

Personalised recommendations